Elena Lopez

Dr. Elena Lopez


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
MBMarc Biarnés
Marc Biarnés
XGXavier Garrell
Xavier Garrell
AGAlba Gómez-Benlloch*
Alba Gómez-Benlloch*
MGMerce Guarro
Merce Guarro
GLGabriel Londoño
Gabriel Londoño
LSLaura Sararols
Laura Sararols
Geographic atrophy (GA) secondary to age-related macular degeneration is a common cause of blindness worldwide. Given the recent approval of the first therapy for GA, pegcetacoplan, we critically appraise methodological aspects of the phase 3 clinical trials published so far in this disease in relation to their design, analysis and interpretation. We reviewed some of the key attributes of all phase 3 clinical trials in GA available in the main public registry of clinical trials as of 20 May 2023. The topics discussed included types of endpoints, eligibility criteria, p-value and effect size, study power and sample size, the intention to treat principle, missing data, consistency of results, efficacy–safety balance and application of results. Five phase 3 clinical trials have reported results, either partially or completely: GATHER1, DERBY/OAKS, CHROMA/SPECTRI, SEATTLE and GATE. Although there are many similarities between these trials in terms of endpoints or broad eligibility criteria, they differ in several aspects (metric of the primary endpoint, sample size, type of adverse events, etc.) that can influence the results, which are discussed. Readers should understand key methodological aspects of clinical trials to improve their interpretation. On the other hand, authors should adhere to clinical trial reporting guidelines to communicate what was done and how it was done.

24 April 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
AGAlba Gómez-Benlloch*
Alba Gómez-Benlloch*
XGXavier Garrell
Xavier Garrell
ECEstefanía Cobos
Estefanía Cobos
ELElena Lopez
Elena Lopez
AEAnna Esteve-Garcia
Anna Esteve-Garcia
MBMarc Biarnés
Marc Biarnés
Macular dystrophies (MDs) constitute a collection of hereditary retina disorders leading to notable visual impairment, primarily due to progressive macular atrophy. These conditions are distinguished by bilateral and relatively symmetrical abnormalities in the macula that significantly impair central visual function. Recent strides in fundus imaging, especially optical coherence tomography (OCT), have enhanced our comprehension and diagnostic capabilities for MD. OCT enables the identification of neurosensory retinal disorganization patterns and the extent of damage to retinal pigment epithelium (RPE) and photoreceptor cells in the dystrophies before visible macular pathology appears on fundus examinations. It not only helps us in diagnostic retinal and choroidal pathologies but also guides us in monitoring the progression of, staging of, and response to treatment. In this review, we summarize the key findings on OCT in some of the most common MD.

24 October 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
LSLaura Sararols
Laura Sararols
MGMerce Guarro
Merce Guarro
MVMeritxell Vázquez
Meritxell Vázquez
SRSergi Ruiz
Sergi Ruiz
ELElena Lopez
Elena Lopez
MBMarc Biarnés
Marc Biarnés
Background/Objectives: This study aimed to characterize the visual performance in patients with bilateral cataracts and a unilateral epiretinal membrane (ERM) undergoing cataract surgery with non-diffractive extended depth of focus (EDoF) intraocular lens (IOL) placement in both eyes and phacovitrectomy in the eye with ERM. Methods: This was a prospective, descriptive, single-arm study. Visual outcomes were measured in monocular and binocular conditions in patients with bilateral cataracts and unilateral ERM stages 2 or 3 implanted with an EDoF IOL. At 6 months, visual acuity (uncorrected and corrected at different distances and contrast levels), contrast sensitivity, and visual disturbances assessed using a Light Distortion Analyzer were determined. Results: We included 22 patients (50% females, mean age of 71.4 ± 5.8 years). Mean monocular best-corrected visual acuities at 100% contrast were 0.07 ± 0.09, 0.23 ± 0.10, and 0.48 ± 0.14 logMAR for eyes with ERM, and 0.02 ± 0.08, 0.19 ± 0.11, and 0.41 ± 0.18 logMAR for fellow eyes for far, intermediate, and near distance vision, respectively. No differences were observed in visual outcomes, contrast sensitivity, or visual disturbances between ERM and non-ERM eyes, except for near distance. No unexpected adverse events were observed. Conclusions: Non-diffractive EDoF IOL can be considered in patients with cataracts and stage 2 or 3 ERM pursuing spectacle independence.

30 October 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
MGMerce Guarro
Merce Guarro
MVMeritxell Vázquez
Meritxell Vázquez
JDJuan Carlos Díaz
Juan Carlos Díaz
SRSergi Ruiz
Sergi Ruiz
MGMaties Gimeno
Maties Gimeno
MBMarc Biarnés
Marc Biarnés
Background/Objectives: This study’s aim was to compare the precision, agreement, and accuracy in axial length (AL) measurements of Argos® (Alcon Healthcare, US) and Eyestar 900® (Haag-Streit, Switzerland) swept-source optical coherence tomography (SS-OCT) biometers. Methods: We performed a prospective evaluation of two diagnostic devices. Three consecutive measurements of AL with the Argos® and the Eyestar® 900 SS-OCT biometers were conducted in random order in eyes undergoing cataract surgery in Barcelona, Spain. The main endpoint was the median difference in AL between devices. Secondary endpoints included agreement on Bland–Altman plots and 95% limits of agreement (LoAs), repeatability as measured within-subject standard deviation (SW), percent of failed AL measurements, percent of eyes within ±0.50 D and ±1.00 D one month after surgery, and median and mean prediction error. Results: We included 107 eyes of 107 patients (60.8% females, mean age of 73.1 years). The median difference in AL (Argos®-Eyestar 900®) was −0.01 mm (interquartile range [IQR], 0.06), p = 0.01. The 95% LoAs were −0.11 to +0.08 mm, with a trend towards less extreme measurements with Argos® for very short and long eyes. The median (IQR) Sw was 0.0058 (0.0058) and 0.0000 (0.0058) for Argos® and Eyestar 900®, respectively. There were no failed AL measurements with either device (0%, 95% CI = 0% to 3.4%). Overall, 96.1% of eyes were within ±0.50 D and 100% were within ±1.00 D. Conclusions: Argos® and Eyestar 900® provided statistically different but clinically negligible differences in AL. However, they are not interchangeable in very long or short eyes, due to the different principles used to determine AL.

4 June 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
MGMerce Guarro
Merce Guarro
LSLaura Sararols
Laura Sararols
ELElena Lopez
Elena Lopez
MVMeritxell Vázquez
Meritxell Vázquez
SRSergi Ruiz
Sergi Ruiz
MBMarc Biarnés
Marc Biarnés
Background/Objectives: The role of the vitreous in the effective lens position (ELP) is controversial in patients undergoing phacovitrectomy. The aim of this study was to compare the change in aqueous depth (AD), a surrogate of the ELP, in non-vitrectomized and vitrectomized fellow eyes. Methods: Post-hoc analysis of a prospective study conducted in OMIQ facilities (Barcelona, Spain) between 2021 and 2023. Patients with bilateral cataracts and a unilateral grade 2/3 epiretinal membrane underwent phacoemulsification in one eye and phacovitrectomy without endotamponade in the fellow eye. All eyes were implanted with an extended depth-of-focus intraocular lens after power calculation using the same biometer, technicians, formula, and surgeon. We compared the change in AD (mm and percentage) from baseline, and the role of vitrectomy without endotamponade on AD with a mixed-effects models. Results: We included 40 eyes (20 patients) with a mean age of 71.6 years, with 55% females. The mean change in AD was +1.51 (vitrectomized) and +1.42 mm (non-vitrectomized eyes), p = 0.33. The percent of change in AD was not different between groups (p ≥ 0.38) and phacovitrectomy had no effect on the change in AD on mixed-effects models (p > 0.10). Conclusions: The absence of the vitreous had a minimal influence on AD in these patients undergoing standard phacoemulsification or phacovitrectomy.